Skip to content
Clinical Trials – home
Not yet recruiting

Neoadjuvant Study of Avelumab with Gemcitabine and Cisplatin versus Chemotherapy Alone in Patients with High‑Grade Localized Upper Tract Urothelial Carcinoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on patients with high‑grade upper tract urothelial carcinoma, a cancer that starts in the lining of the kidney’s collecting system or the ureter. The treatment being tested combines two chemotherapy drugs, gemcitabine and cisplatin, which are given through a vein to kill rapidly growing cells, with an immunotherapy drug called avelumab that helps the immune system recognize and attack cancer cells. Some participants will receive only the chemotherapy drugs, while others will receive the chemotherapy together with the immunotherapy.

The main aim of the research is to see whether adding immunotherapy to standard chemotherapy improves outcomes before surgery. In the study, patients receive a series of intravenous infusions of the assigned medicines over several weeks, followed by the planned surgical removal of the tumor. This approach, known as neoadjuvant treatment, is intended to shrink the tumor and make the operation safer.

After treatment and surgery, participants are followed for several years to track how long they remain free of disease, measured as event-free survival, which means the time without cancer returning, spreading, or causing death. Doctors also examine the removed tissue to determine if a pathologic complete response was achieved, meaning no living cancer cells are found. Throughout the study, safety is monitored by recording any side effects and by regular health questionnaires.

The research process

The trial runs in 10 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization to Treatment Group

    After joining the study, you will be assigned by the study team to one of two treatment groups: the combination group that receives chemotherapy plus immunotherapy, or the chemotherapy‑only group.

  2. Step 2

    Baseline Evaluations

    Before any medication is given, tumor tissue will be collected through a biopsy and blood samples (five tubes of 7 ml each) will be drawn for laboratory analysis.

    You will complete quality‑of‑life questionnaires (EORTC QLQ‑C30 and EORTC QLQ‑BLM30) to record your health status at the start of treatment.

  3. Step 3

    First Treatment Cycle – Chemotherapy Administration

    You will receive gemcitabine at a dose of 1000 mg per square meter of body‑surface area, given intravenously (through a vein).

    You will also receive cisplatin at a dose of 70 mg per square meter, administered intravenously.

  4. Step 4

    First Treatment Cycle – Immunotherapy (If Assigned)

    If you are in the combination group, you will receive avelumab as a single intravenous bolus injection of 800 mg on the same day as the chemotherapy.

  5. Step 5

    Repeated Treatment Cycles

    The chemotherapy drugs (gemcitabine and cisplatin) will be given again at the same doses for each subsequent cycle, following the schedule defined by the study physician (typically every few weeks).

    If you are in the combination group, the immunotherapy drug avelumab 800 mg will also be administered intravenously before each chemotherapy cycle.

    The total number of cycles will continue until the study protocol indicates that enough treatment has been given to proceed to surgery.

  6. Step 6

    Safety Monitoring During Treatment

    Before each cycle, you will have a clinical visit where vital signs, laboratory tests, and any side effects will be recorded.

    Questionnaires about symptoms and quality of life will be completed before each treatment cycle.

  7. Step 7

    Surgical Resection (Neoadjuvant Surgery)

    After completing the prescribed pre‑surgical (neoadjuvant) treatment, you will undergo surgery to remove the tumor from the kidney pelvis or ureter.

    During surgery, the removed tissue will be examined for any remaining cancer cells (pathological complete response).

  8. Step 8

    Post‑Surgery Assessments

    Additional tumor samples will be collected after surgery for further analysis.

    Blood samples will be taken again to compare with the baseline values.

  9. Step 9

    Long‑Term Follow‑Up

    You will be asked to complete the same quality‑of‑life questionnaires at 1 month after surgery, at 3 months, and then every 3 months for up to 3 years.

    Regular clinical visits will include evaluation of disease status, monitoring for any recurrence in the bladder or elsewhere, and assessment of overall health.

    The study will track event‑free survival—the time from the start of treatment until disease progression, recurrence, or death—over a period of 3 years.

  10. Step 10

    Final Study Completion

    At the end of the 3‑year follow‑up period, all final data on survival, disease recurrence, and any lasting side effects will be collected to complete the study.

Who can join the trial?

7 criteria

  • Must be at least 18 years old; if you are older than 70, the study will check your frailty using a short questionnaire called the G8 score.
  • Must have a confirmed diagnosis of high‑grade urothelial carcinoma (a serious type of cancer) in the kidney’s collecting area (renal pelvis) or the tube that carries urine (ureter), proven by a tissue sample taken during a ureteroscopic biopsy (using a thin tube inserted through the urinary tract) or a percutaneous biopsy (using a needle through the skin).
  • Must not have received any previous systemic therapies (cancer medicines that travel throughout the whole body).
  • Must be eligible to undergo the planned surgery called radical nephroureterectomy, which removes the kidney, ureter, and a small part of the bladder.
  • Must have a good overall health rating, measured as ECOG performance status 0 to 1 (meaning you are fully active or only limited in very strenuous activities).
  • Must have a clinical tumor stage assessment (cTNM) that fits the study’s requirements.
  • Both men and women can take part in the trial.

Who cannot join the trial?

7 criteria

  • You cannot join if you also have bladder cancer that is muscle‑invasive (cancer has grown into the muscle layer), in‑situ (cancer cells are still in their original place and have not spread), or a high‑grade tumor that has not yet invaded muscle.
  • You cannot join if you have a serious other medical problem or mental health condition, such as a severe active infection that is currently present.
  • You cannot join if you are taking any other experimental (investigational) medicines at the same time.
  • You cannot join if you have an immunodeficiency (weak immune system) or have taken systemic steroids or other medicines that suppress the immune system within the past 7 days.
  • You cannot join if you have an autoimmune disease (where the immune system attacks the body) that needed treatment with steroids or similar drugs in the last 3 months, or if you have a history of a severe autoimmune disease that required such treatment.
  • You cannot join if you received a live vaccine (a vaccine containing a weakened form of the germ) within 30 days before the first dose of the study drug.
  • You cannot join if you are a woman who is pregnant or breastfeeding, or if you (any gender) could become pregnant and are not willing to use reliable birth control from the start of the study until 90 days after the last dose.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Gemcitabine

    is a chemotherapy drug that is given through a vein. In this study it is part of the standard platinum‑based chemotherapy regimen used before surgery. The medicine works by stopping cancer cells from growing and dividing, helping to shrink the tumor before it is removed.

  • Cisplatin

    is another chemotherapy drug that is also given intravenously. It belongs to the platinum‑based class of medicines and is paired with gemcitabine in the trial’s chemotherapy arm. Cisplatin damages the DNA of cancer cells, which slows or stops their growth, contributing to tumor reduction before surgery.

  • Avelumab

    is an immunotherapy medicine that is given by IV infusion. It is a type of drug called a checkpoint inhibitor, which helps the body’s immune system recognize and attack cancer cells. In this trial, avelumab is added to the gemcitabine‑cisplatin chemotherapy to see if the combination works better than chemotherapy alone in shrinking the tumor before surgery.

What is already known about the treatment

  • Gemcitabine

    Given by intravenous infusion, gemcitabine is an approved chemotherapy drug used for many solid tumors such as bladder, lung and pancreatic cancer. It works by mimicking a building block of DNA, so when cancer cells try to copy their DNA, gemcitabine blocks the process and stops their growth. It belongs to the antimetabolite class of chemotherapy agents and is listed in current medical guidelines and literature as a standard treatment option.

  • Avelumab

    Administered as an intravenous bolus followed by a short infusion, avelumab is a licensed immunotherapy used for cancers like Merkel cell carcinoma and urothelial carcinoma. It is a monoclonal antibody that blocks the protein PD‑L1, helping the body’s immune cells recognise and destroy cancer cells. This drug is classified as a checkpoint inhibitor and is widely described in recent clinical studies as an effective immune‑based therapy.

  • Cisplatin

    Delivered through intravenous infusion, cisplatin is a long‑standing chemotherapy drug approved for a wide range of cancers, including bladder and lung cancers. It attaches to DNA and creates strong links that prevent the DNA strands from separating, which stops cancer cells from dividing and leads to their death. Cisplatin belongs to the platinum‑based chemotherapy class and remains a cornerstone of cancer treatment in current medical practice.

Investigated diseases

High‑grade upper tract urothelial carcinoma - It starts in the lining of the renal pelvis or ureter, where abnormal cells grow quickly. The tumor can extend locally into nearby tissues and spread down the urinary tract. As it advances, it may infiltrate deeper layers and enter the bloodstream, allowing cancer cells to reach distant sites. Recurrence can occur in the bladder after the primary tumor is removed.
Trial detailsLast updated 16 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2024-518311-19-01Protocol codePHRCK/2024/NH01Estimated enrolment434 patientsSponsorCentre Hospitalier Universitaire De Nimes

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.